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Abstract
Background: Epigenetic silencing of RAS association family 1A (RASSF1A) tumor suppressor gene
occurs in various histological subtypes of renal cell carcinoma (RCC) but RASSF1A protein
expression in clear cell RCC as well as a possible correlation with clinicopathological parameters
of patients has not been analyzed at yet.
Methods: 318 primary clear cell carcinomas were analyzed using tissue microarray analysis and
immunohistochemistry. Survival analysis was carried out for 187 patients considering a follow-up
period of 2–240 month.
Results: Expression of RASSF1A was found to be significantly decreased in tumoral cells when
compared to normal tubular epithelial cells. RASSF1A immunopositivity was significantly associated
with pT stage, group stage and histological grade of tumors and showed a tendency for impaired
survival in Kaplan-Meier analysis.
Conclusion: While most tumors demonstrate a loss of RASSF1A protein, a subset of tumors was
identified to exhibit substantial RASSF1A protein expression and show increased tumor
progression. Thus RCC tumorigenesis without depletion of RASSF1A may be associated with an
adverse clinical outcome.
Background
Clear cell renal cell carcinoma (CC-RCC) as the most fre-
quent subtype of RCC has been described to demonstrate
loss and/or alteration of chromosome 3p [1,2]. So far,
some tumor suppressors and candidates have been identi-
fied on 3p, such as FHIT at 3p14.2, VHL at 3p25 and the
RAS association domain family 1A gene (RASSF1A) at
3p21.3. RASSF1A has been detected to undergo promoter
hypermethylation and epigenetic silencing in CC-RCC [3-
7]. The RASSF1A protein contributes to cell cycle control,
stabilization of microtubules, cellular adhesion and
motility [8]. Moreover, RASSF1A interact with the pro-
apoptotic kinase MTS1 and apoptosis-inducing interferon
pathways [9,10]. Depletion of RASSF1A is associated with
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enhanced mitotic progression, a higher risk for chromo-
somal defects [11-13] pronounced cellular motility [14]
and raised tumor susceptibility in knock-out mice [15].
The loss of RASSF1A function due to epigenetic gene
silencing has been detected in various tumor entities,
implicating that RASSF1A is involved in the pathogenesis
of a wide spectrum of tumors [8]. Hypermethylation and
loss of RASSF1A mRNA expression has been shown for
CC-RCC in several studies. While some found methyla-
tion in tumor tissues [3-5,16-18] others reported signifi-
cant methylation occurring also in normal tissue
[3,6,17,18]. Considering that the detection of methyla-
tion occurring in normal tissue together with hypermeth-
ylation detected in corresponding tumor tissue might be
indicative for an involvement of RASSF1A  in the early
tumorigenesis of CC-RCC, we have recently carried out a
study explicitly aiming at the comparison of methylation
in paired normal and tumoral tissues [7].
As a result we found considerable methylation in normal
tissues that becomes significantly increased in corre-
sponding tumor samples. Therefore these results support
the hypothesis that RASSF1A is involved in early tumori-
genesis of CC-RCC. Moreover we found that protein
expression is substantially reduced in tumor cells and in a
subset of normal tubular epithelial cells of histopatholog-
ically normal kidney parenchyma. While these data over-
all demonstrate an inverse relationship of methylation
and protein levels in RCC it is not clear yet whether
RASSF1A levels or the degree of epigenetic silencing is
associated with clinicopathological parameters of RCC
patients. So far, controversial results were reported for
other tumors such as lung adenocarcinoma or non small
cell lung cancer when analyzing a possible association of
RASSF1A expression and grade, stage, metastasis or dis-
ease specific follow up of patients [19-22].
In this study we analyzed the presence of RASSF1A protein
within the primary tumor of clear cell RCCs and benign
surrounding peritumoral tissues using immunohisto-
chemistry (IHC) and tissue microarrays (TMA) and statis-
tically evaluated possible associations of RASSF1A protein
immunopositivity and clinicopathological parameters of
RCC patients.
Materials and methods
Patient characteristics and follow up
The present study included 318 patients, who underwent
radical nephrectomy between 1981 and 1998. Tissue was
obtained from archival routine surgical specimens. The
tissue samples were selected by a pathologist and pre-
pared from the primary tumor as well as peritumoral, his-
tologically benign renal parenchyma and arranged on
tissue micro arrays (TMA) as described previously [23].
Tumor samples were classified primarily according to
UICC 1997 TNM tumor staging system [24]. At the time
of the pathological assessment of our specimens the UICC
2002 version was not available. Moreover, the new path-
ological classification would not influence our results.
Survival analysis was carried out for 187 patients with
complete follow-up data and pathologically proved clear
cell carcinoma of the kidney. The follow up group exhib-
ited a median age of 57.5 years and a mean follow-up
period of 83 (0–248) months (table 1). The male-to-
female ratio was 1.4 to one. Seventeen patients demon-
strated metastasis at the time of diagnosis whereas 170 of
patients had a local tumor in the kidney. However, eight-
een patients without primary metastasis developed metas-
tases in the course of follow up. Thirty of patients without
primary metastasis showed recurrence or metastasis in the
course of follow-up. At the time of the last follow-up
examination, 93 of patients were alive, 67 patients had
died from progressive RCC and 27 patients due to other
causes.
Immunohistochemistry on tissue microarray sections
The paraffin-embedded TMA samples were stained for
RASSF1A protein expression as described previously [7].
Evaluation of TMA's was carried out by counting immu-
nopositive and negative cells within the area of each tissue
microarray punch and the diameter of each spot on the
slides were 1 mm. In tumor tissues only tumor cells were
considered while in peritumoral tissue specimens the
number of immunopositive and negative proximal and
distal tubular cells but not glomerular cells was deter-
mined. The RASSF1A labeling index was calculated as the
percentage of cells of interest displaying immunopositiv-
ity in the analyzed tissue samples (TMA's spots).
Statistical analysis
Statistical analyses were performed using the SPSS statisti-
cal software (Statistical package for social sciences, SPSS,
Inc., Chicago, IL). P-values of < 0.05 were considered sta-
tistically significant. Spearman R nonparametric correla-
tion analysis was used to determine the association
between RASSF1A immunopositivity and clinicopatho-
logical parameters. The Wilcoxon-Mann-Whitney-U-test
was applied for statistical comparison of RASSF1A expres-
sion as observed in distal and proximal tubules of normal
kidney tissue. The possible correlation between cytoplas-
mic expression of RASSF1A and clinicopathological char-
acteristics was determined by the Chi-square test. Survival
was evaluated for patients with RCC of the clear cell type
using the Kaplan-Meier method and the log-rank test or
Cox regression analysis. Cases with cancer-independent
deaths were censored at time of death and included in the
analysis.BMC Urology 2008, 8:12 http://www.biomedcentral.com/1471-2490/8/12
Page 3 of 7
(page number not for citation purposes)
Results
Expression of RASSF1A protein
The presence of RASSF1A protein in primary tumor speci-
mens and corresponding histologically normal surround-
ing parenchyma was investigated using
immunohistochemical analysis of TMA slides of 318
patients with CC-RCC. Specific immunopositivity for
RASSF1A was exclusively observed in the cytoplasm of
tumor and normal tubular epithelial cells [7]. Positivity of
RASSF1A was found to be significantly decreased in
tumoral cells when compared to normal tubular epithelial
cells (p < 0.001, paired t-test). In tumors a mean positivity
of 19% (median 11%) was detected and 85% of tumors
exhibited a RASSF1A labeling index of ≤ 25% (fig. 1 and
2).
Table 1: Patient characteristics
Variable All patients n (%) Follow-up n (%)
Total 318 (100) 187 (100)
pT stage T1 9 (3) 7 (4)
T2 157 (50) 97 (52)
T3 137 (43) 77 (41)
T4 15 (4) 6 (3)
Lymph node N0 162 (51) 96 (51)
N1 34 (11) 17 (9)
Nx 122 (38) 74 (40)
Metastasis M0 235 (74) 138 (74)
M1 63 (20) 35 (19)
Mx 20 (6) 14 (7)
pTNM stage I1 0  ( 3 ) 8  ( 4 )
II 141 (44) 88 (47)
III 100 (31) 56 (30)
IV 67 (22) 35 (19)
Tumor grade G1 53 (17) 36 (19)
G2 200 (62) 134 (72)
G3 25 (8) 10 (5)
G4 1 (0.3) 7 (4)
Unknown 39 (12) 0 (0)
Differential expression of RASSF1A in clear cell carcinoma of the kidney Figure 1
Differential expression of RASSF1A in clear cell carcinoma of the kidney. Immunohistochemical analysis of RASSF1A 
expression in CC-RCC specimens exhibiting < 25% (A) and > 25% (B) labeling index.BMC Urology 2008, 8:12 http://www.biomedcentral.com/1471-2490/8/12
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Considering that most of renal cell carcinomas are
assumed to derive from epithelial cells of the proximal
tubules labeling of RASSF1A protein both in the proximal
and distal tubules of histologically normal materials were
separately analyzed for a subgroup of 90 tissue samples.
An almost complete staining for epithelial cells of the
proximal and distal tubules with labeling index of nearly
100% was observed thus no significant difference of
RASSF1A immunopositivity between proximal or distal
tubules could be found (p = 0.22).
Association between RASSF1A expression and 
histopathological parameters
Whether a correlation between immunopositivity of
RASSF1A (% labeling index) the primary tumor speci-
mens and the histopathological grading and clinical stag-
ing of patients exists, was analyzed using Spearman R
nonparametric correlation analysis. In the primary tumor
specimens a positive correlation between RASSF1A
expression and the pT stage (p = 0.001), histological grad-
ing (p = 0.029) and TNM group stage (p = 0.006) was
detected, whereas no significant correlation was observed
for lymph node metastasis (p = 0.377) and the presence
of distant metastases (p = 0.41; table 2). This indicates
that higher expression of RASSF1A was positively corre-
lated with the higher pT stage, histological grading, and
pTNM group stage in the entire study group.
Taking into account that we recently found a statistical
relationship between cyclinB1 expression, as observed in
the histopathological normal tissues and clinicopatholog-
ical parameters [25] we also compared the RASSF1A
immunopositivity detected in the paired histopathologi-
cally normal specimens to the clinicopathological param-
eters. No significant correlation between expression of
RASSF1A protein in histopathological normal tissue and
the parameters pT-stage, lymph node metastasis, distant
metastasis, histological grading and TNM group stage of
the patients could be detected (data not shown).
Analysis of RASSF1A protein expression and survival of 
patients
Using a cut-off value of 25% for the relative amount of
cells positively stained for RASSF1A in primary tumor
specimens, as suggested by the labeling index (fig. 1) to
allow discrimination of low and high positivity tumors, a
disease-specific survival analysis was performed.
Increased positivity of RASSF1A in the tumor samples
demonstrated a tendency towards decreased survival in
Kaplan-Meier analysis with border line significance (p =
0.054, log rank test), (fig. 3). Using RASSF1A immunopo-
sitivity as a continuous variable and Cox regression for
survival analysis RASSF1A was not identified as a signifi-
cant parameter (p = 0.239, hazard ratio = 1.005, 95% CI
0.997–1.013).
Discussion
RCC is staged conventionally using the TNM staging sys-
tem. However comparable TNM classifications may dem-
onstrate different clinical courses, indicating the need for
additional molecular prognosticators permitting a patient
specific staging and future targeted therapeutic treatment.
The role of RASSF1A as a tumor suppressor gene, its
silencing and loss of function due to methylation in dif-
ferent tumors as well as in RCC has been reported [3-
5,8,26]. Epigenetic inactivation has been observed both in
clear cell and papillary RCC [4,6] however, taking into
account that 85% of RCCs show clear cell carcinoma his-
tology, only this histological subtype was considered in
the present study. To our knowledge this is the first study
Frequency plot of RASSF1A immunopositivity in CC-RCC Figure 2
Frequency plot of RASSF1A immunopositivity in CC-
RCC. Frequency of RASSF1A immunopositivity (% labeling 
index) as observed in clear cell RCC. In approximately 85% 
of tumors a RASSF1A positivity of less than 25% was 
observed.
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Table 2: Relationship of high RASSF1A labeling index (> 25%) 
and clinicopathological parameters for the entire study group (n 
= 318)
Parameter p-value*
pT-stage 0.001
Lymph node status 0.377
Metastasis 0.410
pTNM stage 0.006
Tumor grade 0.029
*Spearman nonparametric correlation analysisBMC Urology 2008, 8:12 http://www.biomedcentral.com/1471-2490/8/12
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immunohistochemically investigating a possible relation-
ship of RASSF1A protein level with clinicopathological
parameters of patients in RCC. Using tissue microarrays
we were able to investigate a large series of specimens of
RCC and corresponding histologically normal tissues in a
single run thus, minimizing inter assay variances. Our
analysis shows that in large part of tumors a loss of
RASSF1A positivity is observed. Hence, our data is in con-
cordance with previous reports describing epigenetic
silencing of the gene in a substantial proportion of RCCs
[4,6]. Therefore, it seems likely that decreased transcrip-
tion of RASSF1A leads to a loss of RASSF1A protein, such
as indicated by our study. Our analysis further supports
the hypothesis that RASSF1A could be involved in
tumourigenesis of a substantial part of clear cell RCC.
Interestingly, we found that a subset of tumors, showing
immunopositivity comparable to that observed in mor-
phologically normal cells, were positively correlated with
T, TNM and grade of tumors. Thus, a higher positivity of
RASSF1A as observed in this subgroup of tumors is signif-
icantly associated with higher stage or grade of tumors but
not lymph node or distant metastasis. Moreover, support-
ing this finding, higher RASSF1A protein levels in tumors
demonstrated a possible association with impaired sur-
vival of patients.
The clinicopathological significance of alterations of
RASSF1A protein levels in tumors has not been described
to our knowledge at yet. However, epigenetic silencing
associated with a loss of RASSF1A has been statistically
analyzed for a relationship with prognostic parameters by
a few studies but showed discordant results so far. Thus it
has been described that hypermethylation of RASSF1A
could be associated with an adverse outcome of patients
exhibiting lung cancer [19,20,27,28] whereas other stud-
ies found no relationship with prognosis [22,29-31].
Therefore, it is currently not clear whether loss of
RASSF1A may serve as a negative molecular prognostica-
tor.
Considering that in our study tumor cells showing normal
levels of RASSF1A instead of the most frequently observed
loss of positivity, were found to be associated with tumor
progression, the question for a potential biological rele-
vance of our findings arises.
Sporadic RCC tumourigenesis has been associated in
about 60% of cases with alteration of VHL thus preventing
ubiquitination and degradation of the transcription factor
hyopoxia induced factor 1α (HIF-) even under normoxia
in kidney cells [32]. As a consequence deregulation of piv-
otal cellular processes in tubular epithelial cells of the kid-
ney, such as angiogenesis, cellular growth and acid-base
balance has been described to be involved in kidney
tumourigenesis. However, it is not known at yet how the
presence or absence of RASSF1A in kidney tumor cells
interacts with the VHL or other pathways of kidney tum-
origenesis.
Loss of RASSF1A expression has been described to be
involved in the majority of RCCs and likely plays a role in
early RCC tumorigenesis. Thus our protein expression
data may give the first evidence that RASSF1A independ-
ent RCC carcinogenesis may also occur in a subset of
tumors and likely is associated with a relatively declined
outcome.
Conclusion
Loss of RASSF1A protein is observed in the majority of
clear cell RCC suggesting a role in RCC tumorigenesis.
Depletion of RASSF1A protein is not a mandatory prereq-
uisite of RCC development as a subset of tumors demon-
strates protein levels comparable to normal cells. RCC
tumorigenesis accompanied by apparently normal levels
of RASSF1A is statistically associated with stage and grade
of tumors and shows a tendency towards decreased sur-
vival. Therefore, it becomes clear that further studies are
necessary to specifically characterize the role of RASSF1A
in particular with respect to the VHL mediated tumouri-
genesis in RCC.
Kaplan-Meier analysis and Hazard Plot Figure 3
Kaplan-Meier analysis and Hazard Plot. Hazard plot 
illustration of Kaplan-Meier analysis. Disease specific survival 
of patients demonstrating either low (< 25% immunoposi-
tively stained tumor cells) or high immunopositivity (> 25%) 
is shown. Borderline significance was obtained using log rank 
test analysis (p = 0.054).
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